AbCellera Biologics (ABCL) Competitors $4.00 -0.06 (-1.36%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. MRUS, CRSP, TGTX, CYTK, ACAD, KRYS, TLX, ADMA, AAPG, and PCVXShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Telix Pharmaceuticals (TLX), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. Its Competitors Merus CRISPR Therapeutics TG Therapeutics Cytokinetics ACADIA Pharmaceuticals Krystal Biotech Telix Pharmaceuticals ADMA Biologics Ascentage Pharma Group International Vaxcyte Merus (NASDAQ:MRUS) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Do analysts recommend MRUS or ABCL? Merus currently has a consensus target price of $88.75, suggesting a potential upside of 33.49%. AbCellera Biologics has a consensus target price of $8.00, suggesting a potential upside of 100.25%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is MRUS or ABCL more profitable? AbCellera Biologics has a net margin of -511.88% compared to Merus' net margin of -685.64%. AbCellera Biologics' return on equity of -16.17% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Merus-685.64% -50.28% -42.00% AbCellera Biologics -511.88%-16.17%-12.24% Do institutionals and insiders have more ownership in MRUS or ABCL? 96.1% of Merus shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.7% of Merus shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer MRUS or ABCL? In the previous week, Merus had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 10 mentions for Merus and 5 mentions for AbCellera Biologics. Merus' average media sentiment score of 1.31 beat AbCellera Biologics' score of 0.39 indicating that Merus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, MRUS or ABCL? Merus has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Which has preferable valuation and earnings, MRUS or ABCL? AbCellera Biologics has lower revenue, but higher earnings than Merus. Merus is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$56.23M89.43-$215.33M-$5.50-12.09AbCellera Biologics$28.83M41.41-$162.86M-$0.55-7.26 SummaryMerus and AbCellera Biologics tied by winning 8 of the 16 factors compared between the two stocks. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$3.09B$5.73B$9.81BDividend YieldN/A2.28%6.66%4.48%P/E Ratio-7.2821.0582.3826.51Price / Sales41.41388.53526.77107.89Price / CashN/A43.5325.7028.92Price / Book1.198.0810.636.55Net Income-$162.86M-$53.35M$3.28B$266.04M7 Day Performance-8.16%-0.15%-0.35%-0.79%1 Month Performance-5.78%9.24%9.99%6.02%1 Year Performance59.80%10.70%48.79%21.97% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.3053 of 5 stars$4.00-1.4%$8.00+100.3%+58.2%$1.20B$28.83M-7.28500MRUSMerus2.9895 of 5 stars$65.74-2.6%$88.64+34.8%+30.0%$4.97B$56.23M-11.9537News CoveragePositive NewsCRSPCRISPR Therapeutics3.5985 of 5 stars$54.13-0.3%$71.60+32.3%+10.4%$4.92B$35M-9.97460Positive NewsAnalyst RevisionTGTXTG Therapeutics4.4178 of 5 stars$28.53-3.1%$46.25+62.1%+26.6%$4.53B$454.07M77.11290News CoveragePositive NewsCYTKCytokinetics4.1137 of 5 stars$37.01-3.5%$71.58+93.4%-13.1%$4.43B$18.47M-7.26250Trending NewsAnalyst ForecastInsider TradeOptions VolumeACADACADIA Pharmaceuticals4.0492 of 5 stars$25.32-1.6%$28.88+14.0%+54.9%$4.27B$1.02B19.04510News CoverageAnalyst RevisionKRYSKrystal Biotech4.8163 of 5 stars$146.77-2.5%$210.38+43.3%-23.6%$4.25B$359.21M29.83210Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.13B$516.72M0.00N/AAnalyst RevisionHigh Trading VolumeADMAADMA Biologics4.014 of 5 stars$17.01-4.4%$27.67+62.6%-0.6%$4.06B$474.17M19.78530Positive NewsAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.04B$134.35M0.00600Positive NewsPCVXVaxcyte2.8065 of 5 stars$30.45-5.7%$136.50+348.3%-60.9%$3.95BN/A-7.41160News CoveragePositive News Related Companies and Tools Related Companies Merus Competitors CRISPR Therapeutics Competitors TG Therapeutics Competitors Cytokinetics Competitors ACADIA Pharmaceuticals Competitors Krystal Biotech Competitors Telix Pharmaceuticals Competitors ADMA Biologics Competitors Ascentage Pharma Group International Competitors Vaxcyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
